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ABSTRACT 
Introduction: Data on adverse drug-reactions (ADR) in the medical field are rare. Objective: To report on the pattern of such problem in a 
multidisciplinary kidney clinic Patients and Methods: Medical records of patients were reviewed retrospectively for such phenomenon in the 
past 6 years Results: A total of 4834 patients were included for analysis.   The unit is responsible for a large proportion of patients with acute 
and chronic kidney diseases of diverse etiologies and multiple co-morbid conditions.  Acute and maintenance dialysis as well as 
immunosuppressive treatment for idiopathic glomerulopathy and autoimmune systemic diseases were common practice.  Results: A total of 
40077 ADR were diagnosed in 4438 patients.  Most patients were adults (39+14) and had median follow up of 38 months. Nearly half of the ADR 
were due to drug-side effects while idiosyncrasy accounted for 1.2%.  The former is due to misuse/abuse of medications while the latter is due to 
genetic, co-morbid conditions or synergetic between 2 drugs or a drug and disease.  Details of drugs ADR are outlined with their respective 
prevalence.  Our study indicates the need for careful auditing of patient’s response during follow up to improve their drug-compliance. 
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INTRODUCTION 
An adverse drug reaction (ADR) is a harmful and unintended 
response to a drug. This includes any undesirable patient’s 
effect suspected to be associated with health product use. 
Unintended effect, health product abuse, overdose, 
interaction (including drug-drug and drug food interactions) 
and unusual lack of therapeutic efficacy are all considered to 
be reportable adverse reactions. A serious ADR is one that 
requires in-patient hospitalization or prolongation of 
existing hospitalization, causes congenital malformation, 
results in persistent or significant disability or incapacity, is 
life-threatening or results in death. ADRs are major public 
health problem in terms of morbidity, mortality, and cost 1.  
In USA, their costs exceeded 4.2 billion annually and 
comprise 3% to 6% of all hospital admissions and complicate 
10% to 15% of hospitalized patients 2.  Data from the 
Arabian Gulf-area, such as Kuwait is limited to a single report 
on 51 referrals collected over 3 years by Al-Rashid allergy 
center 3.  The present study was aimed to shed some lights 
on the extent of the problem in our area. 
 
 
PATIENTS AND METHODS 
Study design: 
Medical records of patients attending El-Reshaid kidney 
clinic from 1st June 2012 to 31st May 2018 were analyzed 
retrospectively for ADRs.  The clinic was established in 1997 
in the capital of Kuwait city.  It is a referral center and 
equipped with adequate diagnostic and therapeutic facilities 
to care for both in- and out-patients with all medical and 
renal diseases.    
Inclusion criteria: 
Patients were included if they had developed a reaction (sign 
and/or symptom) to a given drug that had developed 
immediately and up to weeks later.  A checklist was used to 
report medications of all patients and to define those with 
ADR.  The latter was further classified into: (a) allergic (b) 
delayed hypersensitivity reactions (c) intolerance (d) 
idiosyncrasy (e) misuse/abuse.   
Definitions and classification: 
ADR were classified according to definitions of the 
Committee of World Allergy Organization 3.   
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(a) Allergic ADR refer to IgE-mediated hypersensitivity 
reactions which include urticaria, angioedema and 
anaphylaxis.  (b) Delayed hypersensitivity reactions include 
T-cell mediated immunity viz. drug rash with eosinophilia 
and systemic symptoms (DRESS), erythema multiformis, 
Stevens-Johnson syndrome, toxic epidermal necrolysis.  (c) 
Drug intolerance is an undesirable pharmacologic effect that 
occurs at low and sometimes subtherapeutic doses of the 
drug without underlying abnormalities of metabolism, 
excretion, or bioavailability of the drug.  (d) Drug 
idiosyncrasy is an abnormal and unexpected effect that is 
unrelated to the intended pharmacologic action of a drug. It 
is not mediated by a humoral or cellular immune response 
but is reproducible on readministration. Unlike drug 
intolerance, it is usually due to underlying abnormalities of 
metabolism, excretion, or bioavailability.  (e) Misuse/abuse 
of a drug refers to toxicity to a drug which has been 
inadvertently administered at a higher dose or for a 
prolonged period 
Statistical analysis: 
The mean and + standard deviation were used to describe 
the normally distributed variables viz. age.  However, since 
the duration of follow up was not normally distributed, they 
were expressed as a median and (interquartile range).   
RESULTS 
Over the past 6 years, a total of 4438 patients fulfilled the 
above mentioned criteria and hence were included in the 
study.  The demographical data on the patients are 
summarized in (Table 1). Patients with different age groups 
were included (range: 6-78 years) yet mostly they were 
adults (mean: 39+14) years.  Gender distribution was almost 
equal (Male/Female: 0.9).   Average follow up of those 
patients was (38+18) months.  The initial cause of screening, 
including their co-morbid conditions and the in-patient 
activity are summarized in table 1. 
 
Table 1:  Epidemiological profile of the patients screened   
  Category       No. 
Demographical data: 
    
  
age (years) 
  
39+14 
  
Sex (Male/Female) 
  
0.9 
    Duration of follow up (months)     38(18) 
Initial cause of screening: 
    
 
Renal-related: 
    
  
Acute renal failure: 
  
538 
  
Chronic renal failure 
  
827 
  
Nephrotic syndrome 
  
432 
  
Electrolytes abnormalities 
  
159 
  
Active autoimmune state 
  
276 
 
Co-morbid conditions: 
   
  
Coronary artery disease 
  
557 
  
Infection 
  
340 
  
Uncontrolled diabetes mellitus 
  
458 
  
Uncontrolled hypertension 
  
206 
  
GI-related 
  
437 
  
Autoimmune disease (without renal involvement) 97 
  
Peripheral vascular disease 
  
68 
    Miscellaneous     43 
Grand total:        4438 
In-patient activity: 
    
  
Admissions 
  
283 
  
Observation room 
  
395 
  
Access placement 
  
420 
  
Access complications: 
  
366 
  
Kidney biopsy 
  
136 
  
Skin biopsy 
  
16 
        
Miscellaneous conditons included fractures, malignancy, psychiatric disorders, DVT/PE 
* Age expressed in mean+SD while duration of follow up in meadian (interquartile range) 
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Specific ADR: 
Antibiotics: 
A- Lactam antibiotics: Penicillin allergies were rare for 2 
reasons: (a) rarely used (b) all patients were tested by a 
skin test before its use.  Amoxicillin & cephalosporins 
reactions were rare. (None with EBV had received it).  
However, gastritis was common. 
B- Non-Lactam: 
1- Sulphonamide with/without trimethoprime: gastritis 
was common and 2 cases of EM were associated with it.  
Overall, they were rarely used in chest and urinary tract 
infections because of high incidence of resistance.   
2- Vancomycin: No reaction except for 1 patient who had 
developed red-man syndrome (erythema, pruritis and 
flushing especially in the neck area).  The latter is due to 
non-IgE-mediated histamine release.  He improved after 
slowing the infusion rate and antihistaminics. 
3- Aminoglycosides rarely caused ADR except for misuse 
by not adjusting the dose leading to acute tubular 
necrosis (ATN) and deafness with streptomycin after 2 
weeks treatment for drug-resistant Brucella 
endocarditis.  
4- Quinolones: gastritis was common if the dose in > 250 
mg X2.  Drug allergy was rare with oral and IV 
Ciprofloxacillin compared to multiple incidents with 
acute interstitial nephritis in other quinolones.   
5- Anti-mycobacterial drugs were well tolerated except for 
gastritis.  However, Rifampicin and INH had major 
problems with: 
(a) Pruritis indicating discontinuation in % of patients. 
(b) Abnormal liver functions in %  
6- Diflucan and ampizone: no allergy was reported with 
their use yet the Ampizone has to be given slowly to 
avoid hypotension due to Non-IgE-mediated histamine 
release. 
7- Acyclovir allergy was common despite dose adjustment 
(3/197) compared to 0/65 with gancyclover. 
Diuretics: 
No allergy was noted with Furosamide despite its common 
use for patients with renal and heart failure (0/3031) 
compared to 279/438 with thiazides.  The latter were used 
for prophylaxis in nephrolithiasis & an adjuvant treatment, 
with Furosamide, in refractory edema states. Aldactone-use 
was associated with significant allergy (133/672) which was 
mainly pruritis. 
Antihypertensive: 
1- Allergy was rare except for cough/throat irritation, 
shortness of breath with ACEI 237/2014 and 25/1896 
with ARB compared to none in hundreds to thousands 
treated by others.   
2- Intolerance to antihypertensive leading to drug-
discontinuation was a common problem.  Headache 
with Nifidipine, dependent-edema with Amlodopine, 
constipation with Verapmil.  The latter, was associated 
with major bradycardia with misuse combination with 
betablockers.  Overall, the most tolerated was Diltiazem.  
Oversedation was a major problem with 2 potent drugs 
viz. Aldomet and Clonidine.  Autoimmune hemolytic 
anemia, lupus nephritis and hepatitis were rarely 
reported despite the extensive use of Aldomet. 
3- Hyperkalemia was a major problem in those treated 
with Spiranolactone, beta-blockers and ACEI/ARB 
drugs. 
4- Precipitation of an asthma or heart failure was a 
common problem with beta-blockers. On the other 
hand, direct vasodilators-use was limited in the elderly 
due to sinus tachycardia limiting its use in ischemic 
heart disease patients.  
Anti-platelets: 
Aspirin was responsible for 2/2064 cases of chest allergy 
compared to 166/976 cases of severe pruritis with plavix. 
Statins: No reported allergy with the drugs yet significant 
intolerance of muscle aches with/without rabdomyelisis was 
noted.  Rusovastatin was the least culprit yet the dose cannot 
be increased safely above 40 mg daily for fear of 
rhabdomyelisis.  Evolocumab (Repatha) is an inhibitor 
antibody of proprotein convertase subtilisin kexin type 9.  It 
is a promising drug and in the cases used it was effective and 
without allergy, liver injury and rhabdomyelisis side effects.   
Oral hypoglycemia agents:   
No major allergic phenomenon except for severe metabolic 
acidosis in 2 patients who, by mistake, did not discontinue 
their Metformin at a GFR < 30%.  Metformin was 
discontinued in % of patients for intolerable gastritis and 
DDP-4 for pancreatitis. 
Disease-modifying agents (DMRARDs):  
1- Aspirin/salazopyrines were rarely used. 
2- Methotrexate: no case of interstitial pulmonary fibrosis 
was reported with dose < 6 tab/week.  
Blood products and blood transfusions:  
With erythropoietin blood transfusions were rarely used for 
treatment of anemia of chronic renal failure.  However, 
patients with life-threatening acute bleeds had received 
blood transfusions.  All patients were screened for blood 
groups and rheusus types as well cross match was done 
prior to blood transfusions.  Routine testing for IgA-
deficiency and IgA antibodies were not done.  Fortunately, 
transfusional anaphylaxis was not recorded.  For short-term 
treatment of leucopenia; Filgrastim (Nepogen) was an 
effective and safe agent.  Similar experience was noted with 
Romiplostin (Nplate) for severe thrombocytopenia.  
Protamine sulphate was rarely used for correction of 
overzealous heparinization due to its previous experience 
with allergic reactions and misuse with exaggeration of 
bleeding.  Our approach was to simply use infusions of few 
bags of fresh frozen plasma to correct for overzealous 
anticoagulation.
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Table 2.  The pattern of adverse drug reactions (ADR) encountered with the common drugs
Class ADR (No. & % of total)
Drug Allergic Cytotoxic Intolerance Idiosyncrasy Misuse/abuse Total cases
Antibiotics:
Klacid 1 86 693
Azithromycin 1 11 64
Clindamycin 65 24 862
Amoxicilin 3 69 13 995
Keflex 1 23 186
Zinnat 47 612
Rocephine 2 735
Tazocin 4 1 261
Meropenum 1 1 1892
Vancomycin 2 1892
Amikacin 5 753
Ciprofloxacin 1 56 863
Other quinolones 5 1 27 92
Metronidazole 213(33%) 644
Rifampicin 42(11%) 2 10 27 26 376
Isoniazide 73(17%) 37 13 35 431
Ethambutol 187(71%) 263
Pyrazinamide 2 57 263
Streptomycin 1 2
Diflucan 13 473
Ampizone 3 357
Acyclover 3 2 35 197
Gancyclover 2 65
Diuretics & Antihypertensives:
Furosemide 643(21%) 3031
Thiazides 279(64%) 223(51%) 438
Spiranolactone 133(20%) 289(43%) 672
Adalat LA 298(30% 784
Amlodopine 882(55%) 1608
Lercandipine 67 386
Diltiazem 3 8 1276
Verapmil 132(36%) 32 372
ACEI 43 622(31%) 2014
ARB 12 562(30%) 1896
Beta blockers 257 342 1896
Minipress/Doxazocin 26 185
Minoxidil 38(88%) 12 43
Hydralazine 92 60 293
Clonidine 309(53%) 27 582
methyldopa 605(62%) 2 974
Labetolol 3 12 483
Dilatrend 21 33 861
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Anti-coagulants:  
Hypersensitivity reactions to unfractionated heparin were 
common.  Skin allergy and fever were rare except for 
purpura due to severe thrombocytopenia.  The latter was 
noted with and ½ of the cases were associated with 
spontaneous thrombosis i.e. Heparin-induced 
thrombocytopenia and thrombosis (HITT).  The latter was a 
major practical challenge in management of the acute 
thrombosis and subsequent long-term anti-coagulation.  
Recently, and for unknown reasons, HITT is a major problem 
for our hemodialysis patients.  It may have been related to 
new manufacturing technique which is currently being 
investigated in Kuwait.  Overall, it is our practice to avoid 
Heparin and Warfarin in these patients in the acute phase 
and to use adjusted dose of Fondaparinux since Argatroban 
in not available yet in Kuwait. Warfarin use was associated 
rarely with skin-necrosis but frequent if used early in HIT 
cases. 
Opiates: are rarely used in our patients except for a 
combination of Paracetamol and Codiene to avoid the use of 
NSAIDs for osteoarthrosis and Short course of Tramadol 
with/without Paracetamol in severe preoperative pain.  
Constipation is a major side effect of Codiene and drug-
dependence with Tramadol if misused. 
Local anesthetics: vasovagal attacks were common.  It was 
difficult to discriminate between anxiety and true 
pseudoallergic mechanisms.  All were benign and responded 
to conservative management and the procedure was 
accomplished.  Rarely true allergic reactions or misuse of 
inadvertent intravenous leak of an adrenaline has used 
dysarrythmias. 
Continuation of table 2.  The pattern of adverse drug reactions (ADR) encountered with the common drugs
Class ADR (No. & % of total)
Drug AllergicDelayed hypersensetivityIntolerance Idiosyncrasy Misuse/abuse Total cases
Anti-platelets:
Aspirin 2 5 449 2059
Plavix 166(17%) 976
Anticoagulants:
Heparin 217(12%) 64 1849
LMWH 33 694
Warfarin 4 648(50%) 1286
Xarleto 12 253
Statins:
Simvastatin 144 83(9%) 892
Atrovostatin 231 34 1107
Rusovastatin 26 17 973
Evolocumab 162
Oral anti-diabetic agents:
Biguanides 326 228 1821
Thiazolidinediones 6 2737
2nd G Sulphonylurea 665(40%) 1652
Meglitinides 65 649
Insulin:
Short-acting 328 1728
Long-acting 669(34%) 1978
Mixtard 792(68%) 1159
GLP:
DPP-4: 233 213 376
SGLT-2 inhibitors: 36 62 189
Antiepileptics:
Phenytoin 3 2 32 6 271
Carbamazepine 6 4 12 5 187
Others 3 163
Opiates: 3 5 238(36%) 664
Local anesthetics: 5 136 2 2895
Corticosteroids: 829(40%) 325 2071
Radio-contrast media: 4 47 334(37%) 893
NSAIDs: 529(81%) 253(39%) 42 378(58%) 649
H2-blockers & PPI: 4761
Miscellaneous agents:
Rituximab 26(8%) 1 5 327
Adalimumb 1 29
d-Penicillamine: 2 46
Allopuronol 228(22%) 103 1029
Pregabalin (Lyrica) 247(38%) 61 649
Vitamin D 87 338
Oral iron 83 447(41%) 258 1092
IV iron (Ferinject) 3 1 26 662
Gum Arabia 5 8 8
Grand total: 1887 (2.7%) 14 (0.02%) 6631 (9.5%) 221 (0.3%) 9100 (13 %) 70044
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Radiocontrast media: is a major cause of concern with 
regards the subsequent high incidence of  
ATN in patients with renal impairment.  The use of non-
ionized dye did not decrease incidence of allergy or vomiting 
if proper pre-medication with an antihistaminic is given.  Our 
protocol of hydration with N-acetylcystine for those with 
GFR > 50% was adequate.  Those with GFR < 50% were 
treated with CVVHF 6-12 hours immediately after the dye 
study and did not have significant deterioration of the poor 
kidney function. 
Many patients by mistake did not discontinue their 
Metformin, 3 days prior to the procedure and did not have 
any side effect. 
All patients with history of atopy and hyper-reactive air way 
disease or allergy to radiocontrasts were safe with prior 
antihistaminics and corticosteroids. 
Aspirin allergy: (asthma, rhinitis, sinusitis, urtecaria, 
angioedema) was not encountered. Major concern was 
misuse by combining Aspirin and Warfarin with 2 peptic 
bleeding of which 1 was fatal. However, combining other 
anti-platelets with anticoagulants was seldom a problem if 
dose of the  
NSAIDs: are major concerns for our patients.  They were 
rarely used in our patients for fear of their deleterious effects 
on the kidney.  Acute interstitial nephritis had developed in 
529 
of the 649 patients who had used them.  Acute deterioration 
of dehydrated patients and those with chronic renal disease 
was noted in 253.  Forty two patients had developed acute 
papillary necrosis with them.  A total of 378 patients those 
drugs should not have been used and had resulted in the 
previous side effects as well as gastritis and peptic disease if 
were not pre-medicated with PPI.   
H2-blockers and PPI: were safe drugs and were not 
associated with higher incidence of aspiration pneumonia.   
Miscellaneous group of drugs: 
A- Immunomodulatory agents: Rituximab was used 
extensively in our patients with nephrotic syndrome 
and lupus nephritis as well as patients with severe 
chronic urticaria, pemphigoid and skin vasculitis.  It was 
tolerated in given over 4-6 hours.  Twenty six (8%) had 
severe allergic manifestations that had prevented its 
use.  Adalimumb was used rarely for rheumatoid 
arthritis and inflammatory bowel disease.  One patient 
had developed severe systemic vasculitis 2 weeks after 
its treatment.   
B- d-Pencillamine was used in 46 patients intolerance was 
observed in 2 patients only.   
C- Allopuronol was used for gout which was common in 
our patients due to their renal disease and diuretic-use.  
Moreover, it was used to decrease stone formation.  It 
was associated with high incidence of complications viz. 
acute skin allergy in 228 of the 1029 patients who had 
used it.  Twenty four cases of pancytopenia was 
reported due to its misuse with Azathioprime and 79 
had developed chronic renal deterioration due to it and 
had improved after it discontinuation.  Febuxostat was 
used in 173 patients and had similar pattern of side 
effects. 
D- Pregabalin was used in our patients to control 
neuropathic pains of diabetic peripheral neuropathy, 
cervical and lumber disc disease as well as pain due to 
herpes zoster.  Thirty eight % could not tolerate it for 
drowsiness for severe drowsiness.  Sixty one patients 
had misused or abused it for. 
E- Vitamin D is essential treatment for osteoporosis.  
However, overzealous use, in correcting low levels or 
during pregnancy, was associated with nephrolithiasis. 
F- Oral iron was a major cause of pruritis in 83 of the 1092 
who had use it compared only to 2 with iron 
carboxymaltose (Ferinject). The latter had less 
incidence of allergic manifestations compared with the 
previous iron-dextran or sucrose.  Moreover, gastritis 
and constipation was a common side effect.  
G- Gum Arabia was associated with chronic interstitial 
nephritis with fibrosis was noted in 5 of the 8 patients 
who admitted its use to prolong kidney survival.   
DISCUSSION 
The study of ADR and its monitoring is the concern of the 
field known as “pharmacovigilance”.  In a recent study, 
nearly 80% of physicians were aware of the importance of 
such program for safe practice yet only 15% had reported 
ADR to the concerned centers leading to limited reports on 
this field 4.   In our study, a large number of patients, 
attending a dedicated clinic, were screened and for years in 
an attempt to improve the results of the study.  A total of 
70044 drug-usage that has been recorded in a 4438 patients 
who attended the clinic in the past 6 years. In those patients 
ADR were 17853 (25.5%).  Nearly half (51%) of which, were 
due to drug side-effects while idiosyncrasy accounted only 
for 1.2%.  The former is due to misuse/abuse of medications 
while the latter is due to genetic, co-morbid condition or 
synergetic between 2 drugs or a drug and disease.  The high 
incidence of misuse/abuse emphasizes the value of proper 
training and experience in medicine to avoid such iatrogenic 
disorders.  Moreover, it emphasizes the need for proper 
reporting of ARD for sack of improving health standards and 
patient’s care.  In our study, the most misused/abused drugs 
were diuretics (Furosamide, Thiazides and Spirolactone) 
with or without ACEI and ARB leading to acute renal failure.  
The next group of misused drugs was Warfarin, second 
generation sulphonylurea, Insulins, Opiates, Radiocontrast 
media and NSAIDs.  The latter 2 were a major cause of acute 
renal failure in patients with underlying kidney disease 5.   
The first 4 drugs need proper monitoring of their dosage by 
a experienced physician since their therapeutic window is 
narrow 6.  On the other hand, drug allergy was relatively 
uncommon, accounting for 10.6% of ADR and delayed 
hypersensitivity reactions were rare (0.08%).  Our results 
are in harmony with that reported from UK indicating that 
drug allergy accounts for 10% of all ADR and occurs in 1-2% 
of all admissions and 3-5% of hospitalized patients, 
respectively 2.  However, in our practice, such phenomenon 
was very common with certain drugs viz. NSAIDS with their 
serious side effects on kidney function with acute interstitial 
nephritis 7.  It is followed by thiazide (64%) and Aldactone 
(20%).  Both drugs have renewed interest as first line 
treatment of hypertension, management of refractory fluid 
overload to Furosamide and in cardiac protection protocol 8-
11.  In our study, the second cause of ADR was drug-
intolerance and had a prevalence of 9.5% of and accounted 
for 37% of ADR.  The latter indicates the need for carful 
auditing of the different patient’s response during follow up 
in an attempt to improve drug-compliance 12.  Moreover, 
alternative management plans should be laid out for 
different diseases to overcome such incidents.    
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